MarketCap
Facebook
X
Telegram
Tenax Therapeutics Operating Expenses | TENX
Annual Operating Expenses Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.4 M | 19.5 M | 8.23 M | 11.1 M | 32.7 M | 9.87 M | 8.56 M | 6.89 M | 9.21 M | 19.4 M | 13.8 M | 16.8 M | 6.13 M | 8.55 M | 10.4 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 56.4 M | 6.13 M | 15.8 M |
Quarterly Operating Expenses Tenax Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.8 M | 16.6 M | 16.8 M | 11.8 M | 11.3 M | - | 4.62 M | 3.67 M | 3.91 M | - | 2.12 M | 1.24 M | 1.54 M | - | 2.92 M | 2.86 M | 2.72 M | - | 3.8 M | 1.96 M | 23.7 M | - | 2.23 M | 2.14 M | -2.67 M | - | -2.26 M | -1.82 M | -1.66 M | - | -1.55 M | -1.89 M | -1.22 M | - | -1.31 M | -3.01 M | -3.5 M | - | -4.5 M | -4.67 M | 5.71 M | 3.13 M | 3.1 M | 3.75 M | 3.11 M | 2.47 M | 4.14 M | 4.14 M | 2.42 M | 1.81 M | 2.17 M | 2.17 M | 1.76 M | 2.02 M | 1.2 M | 1.2 M | 1.95 M | 2.78 M | 2.15 M | 2.15 M | 2.45 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.7 M | -4.67 M | 3.09 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Exicure
XCUR
|
4.23 M | $ 1.09 | 3.81 % | $ 6.86 M |  USA |
 |
Cellectis S.A.
CLLS
|
109 M | $ 0.95 | -3.3 % | $ 95.3 M |  France |
 |
AbCellera Biologics
ABCL
|
292 M | $ 12.03 | 1.78 % | $ 3.59 B |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
731 M | $ 58.93 | 1.57 % | $ 7.88 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 55.62 | -0.59 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 29.48 | 0.79 % | $ 1.96 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
8.73 M | $ 3.75 | 2.18 % | $ 45.8 M |  Israel |
 |
Jaguar Health
JAGX
|
36 M | $ 2.36 | 15.44 % | $ 5.5 M | USA |
 |
Protalix BioTherapeutics
PLX
|
54.5 M | $ 2.49 | -2.35 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
128 M | $ 21.65 | -3.5 % | $ 1.24 B |  Niderland |
 |
Stoke Therapeutics
STOK
|
205 M | $ 25.41 | 1.48 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
303 M | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Annexon
ANNX
|
216 M | $ 3.71 | -1.2 % | $ 575 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
10.4 M | $ 1.71 | -4.21 % | $ 2.82 M | Israel |
 |
Incyte Corporation
INCY
|
1.62 B | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
86.7 M | $ 12.43 | 1.22 % | $ 15 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
187 M | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
2.41 B | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 3.24 | -3.72 % | $ 710 M |  Britain |
 |
Catalyst Biosciences
CBIO
|
105 M | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
201 M | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
Evogene Ltd.
EVGN
|
13.8 M | $ 0.37 | 0.44 % | $ 2.91 M | Israel |
 |
EyePoint Pharmaceuticals
EYPT
|
275 M | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
125 M | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
50.9 M | $ 10.12 | 0.4 % | $ 289 M | USA |
 |
Foghorn Therapeutics
FHTX
|
117 M | $ 2.04 | 2.0 % | $ 128 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
119 B | $ 13.76 | 4.13 % | $ 11.5 B |  India |
 |
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 9.91 | 0.71 % | $ 271 M | Israel |
 |
Sanofi
SNY
|
27.3 B | $ 41.77 | 0.41 % | $ 51 B | France |
 |
Arcutis Biotherapeutics
ARQT
|
305 M | $ 31.74 | 1.73 % | $ 4.04 B | USA |
 |
Geron Corporation
GERN
|
252 M | $ 1.15 | 2.23 % | $ 767 M | USA |
 |
Gossamer Bio
GOSS
|
219 M | $ 9.2 | -4.27 % | $ 2.1 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
4.56 M | - | -3.76 % | $ 3.47 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
10.1 M | - | 3.16 % | $ 1.9 M | USA |
 |
ALX Oncology Holdings
ALXO
|
104 M | $ 1.14 | -2.56 % | $ 61.2 M | USA |
 |
Heron Therapeutics
HRTX
|
281 M | $ 0.3 | -0.46 % | $ 50 M | USA |
 |
Achieve Life Sciences
ACHV
|
16.5 M | $ 6.55 | 0.85 % | $ 286 M | USA |
 |
TCR2 Therapeutics
TCRR
|
153 M | - | - | $ 58.1 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
43.9 M | $ 17.02 | 0.98 % | $ 2.29 B | Canada |
 |
iBio
IBIO
|
35.2 M | $ 0.71 | -1.28 % | $ 73.9 M | USA |
 |
ImmuCell Corporation
ICCC
|
9.8 M | $ 10.21 | -0.37 % | $ 92.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
340 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Inhibikase Therapeutics
IKT
|
3.52 M | $ 1.51 | -5.03 % | $ 148 M | USA |
 |
Immunome
IMNM
|
231 M | $ 17.89 | -0.54 % | $ 1.56 B | USA |
|
TFF Pharmaceuticals
TFFP
|
22.6 M | - | -60.05 % | $ 125 K | USA |
 |
InMed Pharmaceuticals
INM
|
11.6 M | $ 1.57 | 9.03 % | $ 6.54 M | Canada |
 |
Inovio Pharmaceuticals
INO
|
86.9 M | $ 0.88 | -1.82 % | $ 41.3 M | USA |
 |
Innoviva
INVA
|
144 M | $ 21.06 | 1.91 % | $ 1.42 B | USA |